Company
Noxopharm Ltd
ASX:NOX
Noxopharm Limited is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
93 stories
Noxopharm enrols final patient cohort for CEP-2 sarcoma trial after clearing second safety milestone
After recently passing the first safety milestone in August, the CEP-2 trial has passed its second safety milestone and we are now able to escalate to the highest dose of Veyonda ever trialled in cancer patients,” CEO Dr Gisela Mautner said
Noxopharm boosts cash position with $5.011 million R&D rebate
“This rebate strengthens our cash position at a time of critical research activity to advance our drug development pipeline,” said CEO Dr Gisela Mautner.
Noxopharm delivers “promising” results from novel pancreatic cancer study
“What makes this study so exciting is that it is the closest you can get to studying human cancer in the laboratory before giving the drug to patients,” says CEO Dr Gisela Mautner.
Noxopharm and UNSW to present pancreatic cancer research at leading US oncology conference
“It is very encouraging to have this abstract accepted by such a prestigious US conference, as it helps raise the international profile of Noxopharm and UNSW, demonstrates the value of the explant model, and shows the potential of our pre-c
Noxopharm CEP-2 sarcoma trial passes Safety Steering Committee milestone
“We appreciate the contributions the eminent clinicians at our trial sites are making towards our goal of developing an effective treatment for this often-fatal group of cancers,” Noxopharm CEO Dr Gisela Mautner said.
Noxopharm given safety committee green light to increase dose in cancer trial; Hungarian site joins up
The DARRT-2 trial of the company’s asset Veyonda® in a combination treatment for prostate, breast and lung cancer has gained momentum with a safety milestone reached and a European trial site added.
Noxopharm lauds participation of Mayo Clinic and Washington University in CEP-2 Sarcoma trial
With the addition of Mayo Clinic and Washington University, Noxopharm has attracted four leading cancer research institutions in the US to participate in its sarcoma trial, assessing the efficacy of Veyonda and doxorubicin in improving outc
Noxopharm collaborator given $1.45 million grant to fund inflammation research
Hudson Institute of Medical Research has been awarded a Victorian Government grant to fund research into novel therapeutics that block inflammation associated with long COVID.
Noxopharm collaborator Hudson Institute secures $100,000 Victorian grant to study RNA-based therapeutics
This grant will fund the laboratory work to establish the therapeutic efficacy of these novel oligonucleotide TLR7 inhibitors in several animal models as well as in primary human cells derived from SLE patients.
Noxopharm welcomes ASCO abstract confirming the immunomodulatory properties of Veyonda®’s active ingredient idronoxil
It is my hope that our work will contribute to the development of new treatments for nasopharyngeal carcinoma," says lead researcher Professor Dora Kwong, commenting on the acceptance of the work as part of ASCO 2022, the leading clinical o
Noxopharm’s Veyonda® secures Orphan Drug Designation from US FDA
“The seven-year period of market exclusivity is commercially extremely valuable, as it means that the FDA will not approve a subsequent drug for the same use within this timeframe,” says CEO.
Noxopharm partner, California’s City of Hope Cancer Center, enrols and doses first patient in trial studying soft tissue sarcoma
The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.
Noxopharm's half-year results include strong cash position and exclusive mRNA licensing agreement
The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.
Noxopharm retrains focus on pancreatic cancer and ends December on solid financial ground
The clinical-stage drug development company is in a strong financial position following a recent R&D rebate, and is well-placed to advance a promising clinical pipeline.
Noxopharm bolsters bank balance with A$5.865 million R&D rebate
The cash injection adds to Noxopharm’s robust cash position, which stood at A$23.6 million as of September 30, 2021.
Noxopharm appoints new CEO to lead it through next stage of development
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” Dr Mautner said.
Noxopharm’s phase two DARRT-2 trial builds momentum with pioneer Aussie trial site
"This phase two study builds on our phase one trial, where we saw promising signals that it may be possible to achieve cancer reduction through the abscopal response,” says CMO.
Noxopharm pulls off ‘major coup’ through Hudson Institute of Medical Research licensing deal for ground-breaking RNA technology
RNA drugs already under development by Hudson will add to existing Pharmorage assets and help position the company at the forefront of chronic inflammatory/autoimmune diseases drug development.
Noxopharm awarded A$8.79 million Australian Government grant for Sarcoma trial
“This grant not only provides substantial non-dilutive funding to Noxopharm, but it also lends external validation to our work. The MRFF awards a limited number of grants, funding only those projects that are highly rated against a series o
Noxopharm begins DARRT-2 trial in the US testing potential ground-breaking immunotherapy
The company believes that DARRT-treatment has the potential to revolutionise cancer treatment by reducing cancer through the abscopal response without many of the unwanted side effects, cost limitations and logistical challenges associated
Noxopharm achieves major clinical milestone with first patient dosed in Veyonda® and Opdivo® IONIC Study
“If we can improve the performance of ICIs by the addition of Veyonda, it could make a massive impact, improving outcomes for cancer patients worldwide. It is exciting that this study is now underway in Australia, and we look forward to upd
Noxopharm has patent claims allowed in Australia and Europe for chemo-enhancing drug Veyonda®
"A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side-effects. Other patients either are too ill or too elderly or just unwilling to even start chemotherapy. That is the gap that we see V
Noxopharm well-funded to advance “rapidly expanding” clinical program
The company is building a pipeline of drugs based on a unique and proprietary technology platform for large markets of unmet medical needs.
Noxopharm buoyed as US Patent Office allows abscopal response claims for Veyonda®
“We see the allowance of this patent application as a major win for the company in our goal of seeing DARRT therapy become a mainstream cancer treatment,” says CEO & MD.
Noxopharm looks ahead to even more highly productive FY22 with clear therapeutic and commercial strategies
The clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome is going into the new financial year in a strong cash position, enabling it to proceed with its exciting Four Pillars Oncology Prog
Noxopharm's Veyonda® may offer other therapeutic opportunities in chronic inflammatory and autoimmune diseases
The discovery of idronoxil's anti-inflammatory mechanism adds a high-profile and potentially high-value drug target for the company’s subsidiary Pharmorage’s emerging pipeline.
Noxopharm to expand NOXCOVID clinical program after “highly encouraging” Phase 1 results of Veyonda® in coronavirus patients
Its partnership with Hudson Institute of Medical Research, NOX has also led to an important discovery about the anti-inflammatory mechanism of action of idronoxil, the active ingredient in Veyonda®.
Noxopharm provides further information on National Cancer Institute partnership
The clinical-stage drug development company’s collaboration with the US National Cancer Institute will run for an initial 12-month term, with the subsequent brain cancer program supported by a fully-costed budget.
Noxopharm collaborates with US National Cancer Institute for brain cancer treatment
The clinical-stage drug development company will team up with an arm of the National Institutes of Health as it investigates a new family of anti-cancer drugs.
Proactive to host Lifesciences Webinar on Tuesday, August 10, featuring three ASX-listed companies
The webinar will be livestreamed on the Proactive YouTube channel, where it can be viewed at any time following the event.
Noxopharm’s pre-clinical study confirms survival advantage of adding Veyonda to LuPSMA Therapy in prostate cancer
It now sees Veyonda having a major commercial future in the rapidly growing field of radioligand therapy, not just in prostate cancer, but across the broad cancer spectrum.
Noxopharm presses ahead with Veyonda® clinical activity over June quarter
Noxopharm is studying its Veyonda® drug candidate across a wide range of medical disciplines, with activity pursued across its oncology, COVID-19, septic shock, chronic inflammatory and autoimmune diseases portfolio.
Noxopharm paves way for US DARRT-2 clinical study on receiving FDA Investigational New Drug approval
With a key regulatory approval in place, Noxopharm is a step closer to starting a multi-national trial on patients with progressive, metastatic prostate, breast or lung cancers using a higher dose of its Veyonda® drug candidate.
Noxopharm secures key European patent allowance for Veyonda® anti-cancer drug candidate
The clinical-stage drug development company believes, if a patent is granted, it will support its ambition to make Veyonda a standard of care drug in combination with major cancer therapies.
Noxopharm accelerates towards Phase 2 trial for DARRT-2 study of anti-cancer drug Veyonda®
The Phase Two trial will broaden the scope of studies into a potential cancer treatment using a higher dose of its Veyonda® drug candidate.
Noxopharm a rare COVID-19 beneficiary with ‘versatile and valuable’ technology platform, says CEO
The company is more than one drug – the business is a drug pipeline based on a novel technology platform that it sees meeting a range of unmet needs of key current interest to the global pharmaceutical industry.
Noxopharm set to benefit from new data showing experimental drug Lu-PSMA-617 to become important treatment for late-stage prostate cancer
Noxopharm welcomes this outcome given its recent LuPIN trial data showing even stronger survival outcome when Lu-PSMA-617 is combined with Veyonda®.
Noxopharm higher on independent trial data supporting Veyonda as major new anti-cancer drug
The key outcome of the World Association of Radiopharmaceutical and Molecular Therapy study is a median overall survival outcome of 11.6 months.
Noxopharm’s NOXCOVID trial achieves full enrolment
In Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in patients with compromised lung function.
Noxopharm will progress to FDA approved breakthrough testing of Veyonda in first-line sarcoma treatment
CEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effect of Veyonda was used to lower dosages of chemotherapy in patients with advanced solid cancers.
Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients
The aim of the CEP-1 study is to show that Veyonda boosts the effectiveness of conventional chemotherapy to allow the use of lower, safer dosages of chemotherapy.
Noxopharm’s interim trial data indicates Veyonda® potentially prevents cytokine storm in patients with moderately severe COVID-19
The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.
Noxopharm files patent for Veyonda® as treatment for septic shock
Compelling COVID-19 pre-clinical data showed idronoxil, the active ingredient in Veyonda, was effective in stopping cytokines, signalling molecules that regulate immune and inflammatory responses.
Noxopharm spin-off Nyrada Inc lists on the ASX after raising $8.5 million
Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.
Noxopharm confirms tolerability of anti-cancer drug candidate Veyonda
The study provides proof-of-concept for well-tolerated chemotherapy with meaningful survival benefit.
Noxopharm and its subsidiary reveal a significant drug discovery
Discovered a compound that is a potent inhibitor of IRAK4 protein which causes chronic inflammation including autoimmune diseases.
Noxopharm raises $10.8 million to accelerate anti-cancer drug development
The company's shares are trading 6% higher intra-day, at $1.06.
Noxopharm attracts $4 million for three drugs targeting unmet medical needs
Each of these three drugs is currently in pre-clinical development.
Noxopharm calls for halt pending clarification of intellectual property
The halt will remain in place until Monday 27th November 2017.
Noxopharm to reveal clinical trial data
The halt will remain in place until Tuesday 21st November 2017.
Noxopharm identifies drug candidate to reduce the impact of human stroke
The company has collaborated with the University of New South Wales.
Noxopharm commences late stage prostate cancer clinical trial
The company has initiated the Phase 1b study involving 24 men.
Noxopharm making steady progress on its anti-cancer drug program
Latest findings signals the potential use of NOX66 in treating malignant brain cancer.
Noxopharm pockets $5.5M to accelerate cancer drug development
NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil.
Noxopharm calls for halt in shares
The halt will remain in place until Wednesday 23rd August 2017.
Noxopharm shares ride higher on initiating anti-cancer trials
NOX66 is as a drug that makes existing therapies work more effectively.
Noxopharm to commence first clinical trial of promising anti-cancer drug
The first-in-human study will involve patients with late-stage cancer.
Noxopharm to begin clinical study of cancer drug in Georgia
Noxopharm Ltd (ASX:NOX) is scheduled to begin its inaugural clinical study of experimental anti-cancer product, NOX66, in December 2016.